|
Name |
Dothideomycetide A
|
Molecular Formula | C25H34O7 | |
IUPAC Name* |
[(3S,8R)-1,9-dihydroxy-1,3,8-trimethyl-2,4-dioxo-5,6,7,8-tetrahydrophenanthren-3-yl] (2R,3R,4S)-3-hydroxy-2,4-dimethylhexanoate
|
|
SMILES |
CC[C@H](C)[C@H]([C@@H](C)C(=O)O[C@]1(C(=O)C2=C3CCC[C@H](C3=C(C=C2C(C1=O)(C)O)O)C)C)O
|
|
InChI |
InChI=1S/C25H34O7/c1-7-12(2)20(27)14(4)22(29)32-25(6)21(28)19-15-10-8-9-13(3)18(15)17(26)11-16(19)24(5,31)23(25)30/h11-14,20,26-27,31H,7-10H2,1-6H3/t12-,13+,14+,20+,24?,25-/m0/s1
|
|
InChIKey |
PHZTWQVIBIBVMW-KMDRFBGRSA-N
|
|
Synonyms |
Dothideomycetide A; CHEMBL3358711; [(3S,8R)-1,9-dihydroxy-1,3,8-trimethyl-2,4-dioxo-5,6,7,8-tetrahydrophenanthren-3-yl] (2R,3R,4S)-3-hydroxy-2,4-dimethyl-hexanoate
|
|
CAS | NA | |
PubChem CID | 66560383 | |
ChEMBL ID | CHEMBL3358711 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 446.5 | ALogp: | 4.1 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 121.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 32 | QED Weighted: | 0.463 |
Caco-2 Permeability: | -4.786 | MDCK Permeability: | 0.00001550 |
Pgp-inhibitor: | 0.872 | Pgp-substrate: | 0.955 |
Human Intestinal Absorption (HIA): | 0.026 | 20% Bioavailability (F20%): | 0.047 |
30% Bioavailability (F30%): | 0.079 |
Blood-Brain-Barrier Penetration (BBB): | 0.693 | Plasma Protein Binding (PPB): | 93.68% |
Volume Distribution (VD): | 1.247 | Fu: | 7.87% |
CYP1A2-inhibitor: | 0.066 | CYP1A2-substrate: | 0.923 |
CYP2C19-inhibitor: | 0.034 | CYP2C19-substrate: | 0.877 |
CYP2C9-inhibitor: | 0.109 | CYP2C9-substrate: | 0.164 |
CYP2D6-inhibitor: | 0.015 | CYP2D6-substrate: | 0.071 |
CYP3A4-inhibitor: | 0.853 | CYP3A4-substrate: | 0.913 |
Clearance (CL): | 3.158 | Half-life (T1/2): | 0.126 |
hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.321 |
Drug-inuced Liver Injury (DILI): | 0.948 | AMES Toxicity: | 0.094 |
Rat Oral Acute Toxicity: | 0.21 | Maximum Recommended Daily Dose: | 0.949 |
Skin Sensitization: | 0.207 | Carcinogencity: | 0.432 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.015 |
Respiratory Toxicity: | 0.919 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004897 | 0.466 | D01CKY | 0.264 | ||||
ENC004896 | 0.393 | D05AFR | 0.238 | ||||
ENC002888 | 0.388 | D08NQZ | 0.235 | ||||
ENC002887 | 0.388 | D0L7AS | 0.234 | ||||
ENC002329 | 0.350 | D08LTU | 0.230 | ||||
ENC002328 | 0.350 | D0WY9N | 0.229 | ||||
ENC004251 | 0.321 | D0T5XN | 0.227 | ||||
ENC003006 | 0.301 | D0I5DS | 0.227 | ||||
ENC005367 | 0.295 | D0R6RC | 0.223 | ||||
ENC002386 | 0.290 | D0J2NK | 0.223 |